Skip to main content
Erschienen in: Clinical Rheumatology 9/2011

01.09.2011 | Original Article

Spontaneous skin regression and predictors of skin regression in Thai scleroderma patients

Erschienen in: Clinical Rheumatology | Ausgabe 9/2011

Einloggen, um Zugang zu erhalten

Abstract

Skin tightness is a major clinical manifestation of systemic sclerosis (SSc). Importantly for both clinicians and patients, spontaneous regression of the fibrosis process has been documented. The purpose of this study is to identify the incidence and related clinical characteristics of spontaneous regression among Thai SSc patients. A historical cohort with 4 years of follow-up was performed among SSc patients over 15 years of age diagnosed with SSc between January 1, 2005 and December 31, 2006 in Khon Kaen, Thailand. The start date was the date of the first symptom and the end date was the date of the skin score ≤2. To estimate the respective probability of regression and to assess the associated factors, the Kaplan–Meier method and Cox regression analysis was used. One hundred seventeen cases of SSc were included with a female to male ratio of 1.5:1. Thirteen patients (11.1%) experienced regression. The incidence rate of spontaneous skin regression was 0.31 per 100 person-months and the average duration of SSc at the time of regression was 35.9 ± 15.6 months (range, 15.7–60 months). The factors that negatively correlated with regression were (a) diffuse cutaneous type, (b) Raynaud’s phenomenon, (c) esophageal dysmotility, and (d) colchicine treatment at onset with a respective hazard ratio (HR) of 0.19, 0.19, 0.26, and 0.20. By contrast, the factor that positively correlated with regression was active alveolitis with cyclophosphamide therapy at onset with an HR of 4.23 (95% CI, 1.23–14.10). After regression analysis, only Raynaud’s phenomenon at onset and diffuse cutaneous type had a significantly negative correlation to regression. A spontaneous regression of the skin fibrosis process was not uncommon among Thai SSc patients. The factors suggesting a poor predictor for cutaneous manifestation were Raynaud’s phenomenon, diffuse cutaneous type while early cyclophosphamide therapy might be related to a better skin outcome.
Literatur
1.
Zurück zum Zitat Mayes MD, Lacey JV, Beebe-Dimmer J et al (2003) Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 48(8):2246–2255PubMedCrossRef Mayes MD, Lacey JV, Beebe-Dimmer J et al (2003) Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 48(8):2246–2255PubMedCrossRef
2.
Zurück zum Zitat Silman AJ (1997) Scleroderma—demographics and survival. J Rheumatol Suppl 48:58–61PubMed Silman AJ (1997) Scleroderma—demographics and survival. J Rheumatol Suppl 48:58–61PubMed
3.
Zurück zum Zitat Steen VD, Oddis CV, Conte CG, Janoski J, Casterline GZ, Medsger TA (1997) Incidence of systemic sclerosis in Allegheny County, Pennsylvania. A twenty-year study of hospital-diagnosed cases, 1963–1982. Arthritis Rheum 40(3):441–445PubMedCrossRef Steen VD, Oddis CV, Conte CG, Janoski J, Casterline GZ, Medsger TA (1997) Incidence of systemic sclerosis in Allegheny County, Pennsylvania. A twenty-year study of hospital-diagnosed cases, 1963–1982. Arthritis Rheum 40(3):441–445PubMedCrossRef
4.
Zurück zum Zitat Czirják L, Foeldvari I, Müller-Ladner U (2008) Skin involvement in systemic sclerosis. Rheumatology (Oxford) 47(Suppl 5):v44–v45CrossRef Czirják L, Foeldvari I, Müller-Ladner U (2008) Skin involvement in systemic sclerosis. Rheumatology (Oxford) 47(Suppl 5):v44–v45CrossRef
5.
Zurück zum Zitat Brennan P, Silman A, Black C et al (1992) Reliability of skin involvement measures in scleroderma. The UK Scleroderma Study Group. Br J Rheumatol 31(7):457–460PubMedCrossRef Brennan P, Silman A, Black C et al (1992) Reliability of skin involvement measures in scleroderma. The UK Scleroderma Study Group. Br J Rheumatol 31(7):457–460PubMedCrossRef
6.
Zurück zum Zitat Black CM (1995) Measurement of skin involvement in scleroderma. J Rheumatol 22(7):1217–1219PubMed Black CM (1995) Measurement of skin involvement in scleroderma. J Rheumatol 22(7):1217–1219PubMed
7.
Zurück zum Zitat Verrecchia F, Laboureau J, Verola O et al (2007) Skin involvement in scleroderma—where histological and clinical scores meet. Rheumatology (Oxford) 46(5):833–841CrossRef Verrecchia F, Laboureau J, Verola O et al (2007) Skin involvement in scleroderma—where histological and clinical scores meet. Rheumatology (Oxford) 46(5):833–841CrossRef
8.
Zurück zum Zitat Furst DE, Clements PJ, Steen VD et al (1998) The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol 25(1):84–88PubMed Furst DE, Clements PJ, Steen VD et al (1998) The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol 25(1):84–88PubMed
9.
Zurück zum Zitat Furst DE (2008) Outcome measures in rheumatologic clinical trials and systemic sclerosis. Rheumatology (Oxford) 47(Suppl 5):v29–v30CrossRef Furst DE (2008) Outcome measures in rheumatologic clinical trials and systemic sclerosis. Rheumatology (Oxford) 47(Suppl 5):v29–v30CrossRef
10.
Zurück zum Zitat Pope JE, Bellamy N (1993) Outcome measurement in scleroderma clinical trials. Semin Arthritis Rheum 23(1):22–33PubMedCrossRef Pope JE, Bellamy N (1993) Outcome measurement in scleroderma clinical trials. Semin Arthritis Rheum 23(1):22–33PubMedCrossRef
11.
Zurück zum Zitat Matsushita T, Hasegawa M, Hamaguchi Y, Takehara K, Sato S (2006) Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis. J Rheumatol 33(2):275–284PubMed Matsushita T, Hasegawa M, Hamaguchi Y, Takehara K, Sato S (2006) Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis. J Rheumatol 33(2):275–284PubMed
12.
Zurück zum Zitat Anonymous (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 23(5):581–590 Anonymous (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 23(5):581–590
13.
Zurück zum Zitat LeRoy EC, Black C, Fleischmajer R et al (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15(2):202–205PubMed LeRoy EC, Black C, Fleischmajer R et al (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15(2):202–205PubMed
14.
Zurück zum Zitat Panicheewa S, Chitrabamrung S, Verasertniyom O et al (1991) Diffuse systemic sclerosis and related diseases in Thailand. Clin Rheumatol 10(2):124–129PubMedCrossRef Panicheewa S, Chitrabamrung S, Verasertniyom O et al (1991) Diffuse systemic sclerosis and related diseases in Thailand. Clin Rheumatol 10(2):124–129PubMedCrossRef
15.
Zurück zum Zitat Vancheeswaran R, Azam A, Black C, Dashwood MR (1994) Localization of endothelin-1 and its binding sites in scleroderma skin. J Rheumatol 21(7):1268–1276PubMed Vancheeswaran R, Azam A, Black C, Dashwood MR (1994) Localization of endothelin-1 and its binding sites in scleroderma skin. J Rheumatol 21(7):1268–1276PubMed
16.
Zurück zum Zitat Vancheeswaran R, Magoulas T, Efrat G et al (1994) Circulating endothelin-1 levels in systemic sclerosis subsets—a marker of fibrosis or vascular dysfunction? J Rheumatol 21(10):1838–1844PubMed Vancheeswaran R, Magoulas T, Efrat G et al (1994) Circulating endothelin-1 levels in systemic sclerosis subsets—a marker of fibrosis or vascular dysfunction? J Rheumatol 21(10):1838–1844PubMed
17.
Zurück zum Zitat Sunderkotter C (2006) Pathophysiology and clinical consequences of Raynaud’s phenomenon related to systemic sclerosis. Rheumatology 45(Supplement 3):iii33–iii35PubMedCrossRef Sunderkotter C (2006) Pathophysiology and clinical consequences of Raynaud’s phenomenon related to systemic sclerosis. Rheumatology 45(Supplement 3):iii33–iii35PubMedCrossRef
18.
Zurück zum Zitat Wang R, Ghahary A, Shen YJ, Scott PG, Tredget EE (1997) Nitric oxide synthase expression and nitric oxide production are reduced in hypertrophic scar tissue and fibroblasts. J Invest Dermatol 108(4):438–444PubMedCrossRef Wang R, Ghahary A, Shen YJ, Scott PG, Tredget EE (1997) Nitric oxide synthase expression and nitric oxide production are reduced in hypertrophic scar tissue and fibroblasts. J Invest Dermatol 108(4):438–444PubMedCrossRef
19.
Zurück zum Zitat Knock GA, Terenghi G, Bunker CB, Bull HA, Dowd PM, Polak JM (1993) Characterization of endothelin-binding sites in human skin and their regulation in primary Raynaud’s phenomenon and systemic sclerosis. J Invest Dermatol 101(1):73–78PubMedCrossRef Knock GA, Terenghi G, Bunker CB, Bull HA, Dowd PM, Polak JM (1993) Characterization of endothelin-binding sites in human skin and their regulation in primary Raynaud’s phenomenon and systemic sclerosis. J Invest Dermatol 101(1):73–78PubMedCrossRef
20.
Zurück zum Zitat Calguneri M, Apras S, Ozbalkan Z et al (2003) The efficacy of oral cyclophosphamide plus prednisolone in early diffuse systemic sclerosis. Clin Rheumatol 22(4–5):289–294PubMedCrossRef Calguneri M, Apras S, Ozbalkan Z et al (2003) The efficacy of oral cyclophosphamide plus prednisolone in early diffuse systemic sclerosis. Clin Rheumatol 22(4–5):289–294PubMedCrossRef
21.
Zurück zum Zitat Apras S, Ertenli I, Ozbalkan Z et al (2003) Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis. Arthritis Rheum 48(8):2256–2261PubMedCrossRef Apras S, Ertenli I, Ozbalkan Z et al (2003) Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis. Arthritis Rheum 48(8):2256–2261PubMedCrossRef
22.
Zurück zum Zitat Caramaschi P, Canestrini S, Martinelli N et al (2007) Scleroderma patients nailfold videocapillaroscopic patterns are associated with disease subset and disease severity. Rheumatology 46(10):1566–1569PubMedCrossRef Caramaschi P, Canestrini S, Martinelli N et al (2007) Scleroderma patients nailfold videocapillaroscopic patterns are associated with disease subset and disease severity. Rheumatology 46(10):1566–1569PubMedCrossRef
Metadaten
Titel
Spontaneous skin regression and predictors of skin regression in Thai scleroderma patients
Publikationsdatum
01.09.2011
Erschienen in
Clinical Rheumatology / Ausgabe 9/2011
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-011-1744-z

Weitere Artikel der Ausgabe 9/2011

Clinical Rheumatology 9/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

VHF-Ablation nützt wohl nur bei reduzierter Auswurfleistung

02.05.2024 Ablationstherapie Nachrichten

Ob die Katheterablation von Vorhofflimmern bei Patienten mit Herzinsuffizienz die Komplikationsraten senkt, scheint davon abzuhängen, ob die Auswurfleistung erhalten ist oder nicht. Das legen die Ergebnisse einer Metaanalyse nahe.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.